Born: 1960
Background: Magnus is medical doctor and PhD from the Karolinska Institute in Sweden and co-founder of the now publicly traded Aerocrine. He has been working as a clinical doctor and early in his career he was in charge of several clinical trial programs for Sanofi that resulted in blockbuster drugs. Magnus has a long history in the pharmaceutical industry and has built up investment funds both in Sweden and abroad with a focus on medical projects – particularly as Partner at HealthCap in Sweden from inception and later as Managing Partner in San Francisco based The Column Group. In these capacities Magnus helped found and develop many successful biotech companies.
Independent in relation to the company and management: Yes
Independent in relation to major shareholders: Yes
Holdings in the company: Magnus holds 256,686 shares in the Company.
Warrants: 65,000
Born: 1949
Background: Dr. Ando brings 45 years of experience as one of the most experienced and respected leaders in the global pharmaceutical industry. Dr. Ando is the retired Chair of the Board of Novo Nordisk A/S, a global pharmaceutical company and the current Chairman of EyePoint Pharmaceuticals (USA), Nouscom (Switzerland) and Nanexa AB (Sweden).
Dr. Ando’s career began in the pharmaceutical industry in 1978 as Medical Director of Pfizer AB, progressing to Director, Clinical Research with Pfizer International in the US. He then became VP, Medical and Scientific Affairs at Bristol-Myers, returning to Sweden as President of the Astra Research Centre. Between 1989 and 1995, he held various senior appointments at Glaxo, including R&D Director for Glaxo Group Research.
Dr. Ando joined Pharmacia AB in 1995 as EVP and Deputy CEO, moving to the U.S. in 1997 to lead R&D with additional responsibilities for manufacturing, information technology, business development and M&A. During his eight-year tenure as Head of R&D at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food & Drug Administration prior to Pharmacia’s acquisition by Pfizer for $60 billion.
Dr. Ando was then appointed CEO of Celltech Group PLC in the United Kingdom, one of the most successful European biotech companies, until it was acquired by UCB Pharma for $3 billion in 2005. Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.
Independent in relation to the company and management: Yes
Independent in relation to major shareholders: Yes
Holdings in the company: –
Warrants: –
Born: 1965
Background: Annette has more than 30 years’ experience from different functions within finance and management in executive positions as CEO, Group CFO, COO, Group Financial Controller and Tax Manager, including 20 years in Life Science. Annette has been part of fast-growing companies and organizations and has long experience in building strategic plans, building teams, streamlining infrastructure M&A, IPO and funding experience. She worked with both Venture Capital and Private Equity owners, however the majority in publicly listed companies. Most recent assignments include Boule Diagnostics AB (publ), Biotage AB (publ), Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. Annette has her own consultant/advisory company since 2008. Besides from that she also has board assignments in Sozap AB (publ), ProstaLund AB (publ), NorrDia AB and Colinex Capital AB. Annette has education in Business Administration, from Lund University, Sweden.
Independent in relation to the company and management: Yes
Independent in relation to major shareholders: Yes
Holdings in the company: Annette holds 17,000 shares in the Company.
Warrants: 53,000
Gunilla is medical doctor, PhD and associate professor from the Karolinska Institutet in Sweden and co-founder of Gesynta Pharma AB. Gunilla started her professional career in the pharma industry as scientist within drug metabolism. Later on, she moved on to project work and established cross functional, high-performance teams, responsible for a portfolio of projects for global development within analgesia, bringing compounds from discovery up to clinical phase 2. The role involved long term strategic plans, budgets, evaluation of in licensing opportunities and due diligence. As a member of an executive management team of a public company, Dr. Ekström was involved in financing, prioritization of the portfolio, personnel and worked close to the board.
Dr. Ekström have experience from the entire R&D value chain (discovery to NDA) and from small, mid-sized and large pharma companies. She has held positions as CEO of virtual companies and has held several board positions.
Independent in relation to the company and management: Yes
Independent in relation to major shareholders: Yes
Holdings in the company: Gunilla holds 7,000 shares in the Company.
Warrants: 42,000
Born: 1974
Background: Claus earned his PhD in Physiology and Biophysics from Aarhus University in 2008 and has been engaged in both basic and applied research with an emphasis on structural biology and function of membrane proteins ever since. Furthermore, Dr. Olesen has been in involved in numerous drug development projects in both academic and industrial collaborations with both soluble and membrane protein targets. He is the author of a number of articles including two first authorship articles in Science and Nature. He is the co-founder of Pcovery ApS (2009) an antifungal Biotech situated in Copenhagen and NMD Pharma (2015) a biotech company focused on the development of new treatments for neuromuscular disorders. He is the coordinator of the Business Research Manager program at the faculty of Health at Aarhus University aimed at establishing more collaboration between the research at the university and pharmaceutical industry. He is former professional sailor having competed in the Americas Cup for Sweden in 2003 and participating in two Olympics representing Denmark (2004 & 2012)
Holdings in the company: Claus holds 1,072,438 shares in the Company.
Warrants: 510,000
Independent in relation to the company and management: No
Independent in relation to major shareholders: Yes
Born: 1974
Background: Peter has a PhD in biochemistry from the Karolinska in Stockholm, and a Master’s degree in chemistry from the University of Linköping. Holm is a partner and European Patent Attorney at the Patent & Trademark Office Høiberg. Holm has extensive experience in strategic global IPR and commercialization advisory services to companies and organizations in the life science sector.
Independent in relation to the company and management: Yes
Independent in relation to major shareholders: Yes
Holdings in the company: –
Warrants: –